Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vu Ho

Facial Plastic Surgery Plano, TX Medical Doctor

NPI 1528071826 CMS profile 720282

6213 Chapel Hill Blvd Ste A, Plano, TX 75093

Open in the dashboard

General payments

$33,116

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vu Ho of Plano, TX is reported in the CMS Open Payments database as having received $33,116 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $958 21
2024 General $1,227 34
2023 General $474 17
2022 General $392 17
2021 General $10,278 18
2020 General $6,600 4
2019 General $13,187 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vu Ho
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Vu Ho were reported at $958. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Vu Ho Facial Plastic Surgery median Middle half National median
2019 $13,187 $225 $92–$651 $163
2020 $6,600 $132 $45–$323 $114
2021 $10,278 $186 $67–$558 $132
2022 $392 $218 $83–$594 $149
2023 $474 $237 $94–$564 $160
2024 $1,227 $233 $104–$575 $164
2025 $958 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $30,606 62 payments
  2. AbbVie, Inc. $1,932 53 payments
  3. Allergan Inc. $245 12 payments
  4. Pacira Pharmaceuticals Incorporated $121 1 payment
  5. Heron Therapeutics, Inc. $117 1 payment
  6. Lilly USA, LLC $33 2 payments
  7. Daiichi Sankyo Inc. $29 1 payment
  8. Sun Pharmaceutical Industries Inc. $16 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,300 10 payments
  2. Food and Beverage $3,727 110 payments
  3. Travel and Lodging $1,063 11 payments
  4. Education $25 3 payments
Products named General payments · program years 2019–2025
  1. BOTOX $1,220 41 payments
  2. DYSPORT $183 3 payments
  3. EXPAREL $121 1 payment
  4. Zynrelef $117 1 payment
  5. DYSPORT $72 4 payments
  6. BOTOX COSMETIC $62 4 payments
  7. VERZENIO $33 2 payments
  8. ENHERTU $29 1 payment
  9. NATRELLE SALINE-FILLED BREAST IMPLANTS $25 1 payment
  10. CYRAMZA $17 1 payment
  11. Other $63 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record